Diamond
Cancer patients receive a variety of treatments, including anticancer drugs and antibiotics, during chemotherapy, and their immune system often changes due to diabetes, high blood pressure, and other systemic diseases. Because there is no tool to measure it, the impact of the patient's immune status on existing treatment, the patient's survival time remains uncertain.
The number of white blood cells, red blood cells, platelets, etc. only reflects the degree of vulnerability to infection or bleeding and cannot be used as a prediction or prognostic factors for the treatment.
Additionally, various inflammatory cells, including T lymphocytes, can only be tested at the laboratory level, so it has limitations to implement to routine clinical practice. So, we are trying to develop an indicator that can simply analyze the patient's immune status and evaluate its usefulness by using various parameters of the XN instrument, Sysmex's Hematology Analyzer.